U-PGx Clinician`s Questionnaire

QUESTIONNAIRE for PHARMACISTS and PHYSICIANS

To whom the questionnaire addresses:

- physicians (treating and dosing patients)
- hospital pharmacists (therapy adjustments, dose adjustments)

Introduction

This is an anonymous questionnaire to evaluate the views and knowledge of current drug prescribers on pharmacogenomics and its role in individualizing patient treatment. This study is part of the work being carried out by a pan-European research collaboration called Ubiquitous Pharmacogenomics (U-PGx: http://upgx.eu/). The results of this questionnaire will support the development of a short e-Learning Tool on pharmacogenomics for clinicians and pharmacists. This questionnaire is anonymous. However, the outcome of the questionnaire will be published in a scientific journal. We are grateful to you for taking the time to answer the following questions.



U-PGx | Ubiquitous Pharmacogenomics



SECTION 1: EXPERIENCE AND ATTITUDE

1)					
Please rank.		disagree			agree
		1	2	3	4
Pharmacogenomics is relevant to my current pr	actice.	0	0	0	0
2)					
How are you involved in the U-PGx project?		o I am n	ot invol	lved at a	II
	her, please specify)	o I treat o I adjus recomm o I ordei o other:	t doses endation tests b	/provide ons oy mysel	9
3)	ala antina antina la ana	- :al:a			
In general, on which of the following do you pre your drug dosing?	dominantly base	o indicat			
(please select all that apply)		o body so o renal for o liver for o age o sex o therapor o bioma o comor o come o	curface function neutic d nacogen rker bidities	rug mon nomics	itoring
(if ot	her, please specify)	o other:			



U-PGx | Ubiquitous Pharmacogenomics

cs ****

4a)

How many times did you order/ recommend a pharmacogenomics test last year? o 0 o 1/ month o 2-5/ month o 6-10/ month o 11-20/ month o >20/ month

4b)

	,	
	Please select why you would <u>not</u>	o not applicable
	order a test:	o concerns about privacy
	(please select all that apply)	o little-or-no, or uncertain about the value of testing
		o lack of insurance coverage for testing
		o not enough personal knowledge about genomic testing
		o not familiar with the legal issues and regulations of pharmacogenomics testing
		o patients' resistance to genomic testing
		o I do not prescribe drugs with genomic tests
		available or recommended
	(if other, please specify)	o other:
	4c)	
	If ≥1, could you use the test result?	o Yes
		o No, I did not know how to interpret it.
		o No, because it took too long for the
		pharmacogenomics test result to come back
	(15.11)	o There was no abnormality.
	(if other, please specify)	o other:
	4d)	
	If ≥1, who paid for the test? (one)	o patient
		o clinic
	(if other places are sife.)	o health insurance
	(if other, please specify)	o other:

5)


•,		
Why do you usually order phar	rmacogenomics tests?	o obligatory companion diagnostic
(please select all that apply)		o preventing/ explaining side effects o dose adjustments
		•
		o for research purposes
		o tumour diagnostic
		o not applicable
	(if other, please specify)	o other:



SECTION 2: KNOWLEDGE

Please 6a)	rank your perceived knowledge on a scale.	disagree 1	2	3	agred
I am familiar with classical genetics.		0	0	0	0
	6b)				
	Where did you learn about this topic?	o univer	sity		
		-		ff memb	er
		o confer			
		o journa			
		o intern	et		
	(15.1)	o never			
	(if other, please specify)	o other:			
	6c)	- 4.3			
	When did you learn about this topic the last time?	o 1-2			
	(How many years ago?)	o 2-3 o 3-5			
		o 5-10			
		o >10			
		o never			
		O HEVEI			
Please	rank your perceived knowledge on a scale.	disagree			agre
7a)	rame your perceived knowledge on a souler	1	2	3	4
I am familiar with pharmacology and drug metabolism.		0	О	0	О
	7b)				
	Where did you learn about this topic?	o univer	sity		
		o as a ju	nior sta	ff memb	er
		o confe			
		o journa			
		o intern	et		
		o never			
	(if other, please specify)	o other:			
	7c)				
	When did you learn about this topic the last time?	o 1-2			
	(How many years ago?)	o 2-3			
		0 3-5			
		o 5-10			
		o >10			
		o never			





		rank your perceived knowledge on a scale.	disagree			agree
	8a)		1	2	3	4
	I am fai	miliar with pharmacogenomics.	0	0	0	0
		8b)				
		Where did you learn about this topic?	o univer			
			o as a ju		iff memb	per
			o confer			
			o journa			
			o intern	et		
		(Catherine James 1975)	o never			
		(if other, please specify) 8c)	o other:			
		When did you learn about this topic the last time?	o 1-2			
		(How many years ago?)	o 2-3			
			o 3-5			
			o 5-10			
			o >10			
			o never			
	Please	rank your perceived knowledge on a scale.	disagree			agree
	9a)	, ,	1	2	3	4
I am familiar with the role of drug metabolizer phenotypes (e.g. a		0	0	0	0	
poor metabolizer).						
		9b)				
		Where did you learn about this topic?	o univer	sity		
			o as a ju	ınior sta	iff memb	oer
			o confer			
			o journa	al		
			o intern	et		
			o never			
		(if other, please specify)	o other:			
		9c)				
		When did you learn about this topic the last time?	o 1-2			
		(How many years ago?)	o 2-3			
			o 3-5			
			o 5-10			
			o >10			
			o never			



I am familiar with interpreting the results of pharmacogenomics

U-PGx | Ubiquitous Pharmacogenomics

		î	* * *
Please rank your perceived knowledge on a scale.	disagree		agree
10a)	1 2	3	4

4413	
10b)	
Where did you learn about this topic?	o university o as a junior staff member
	o conference
	o journal
	o internet
	o never
(if other, please specify)	o other:
10c)	
When did you learn about this topic the last time?	o 1-2

	(/ //		
10c)			
When did you learn about this top	ic the last time?	o 1-2	
(How many years ago?)		o 2-3	
		o 3-5	
		o 5-10	
		o >10	
		o never	

11)

tests.

What sources of information have you used to learn about pharmacogenomics testing and its application to drug prescribing?

application to alab bi escribing	•	
(please select all that apply)		o drug labels (package insert) o genetic testing laboratory o colleague/ other physician o pharmgkb website o youtube o other internet site o journal o none
	(if other, please specify)	o other:

0

SECTION 3: KNOWLEDGE TESTING

Please answer the following questions to the best of your knowledge (select one answer only per question).

12)

What may be the consequence of a pharmacogenomic polymorphism?

- o an individual cannot metabolize any drugs
- o an individual has a higher risk for toxicity when using prescription drugs
- o a single drug dose is appropriate for a given indication
- o individualized dose adjustments should be made according to body surface area

13)

The European Medicine Agency currently includes pharmacogenomics information in the drug labels of how many medications?

o 5-10

o 11-50

o 51-100

o >100

14)

What does a poor metabolizer (PM) phenotype indicate?

- o lower drug safety because of poor metabolism
- o good drug efficacy because of poor metabolism
- o decreased enzyme activity
- o increased enzyme activity

15)

A person who is a PM for CYP2D6 gets a medication that induces CYP2D6. What may be a consequence?

- o decreased CYP2D6 activity
- o no activity of CYP2D6, no consequence
- o increased CYP2D6 activity
- o the person becomes and intermediate metaboliser (IM) for CYP2D6

SECTION 4: NEEDS ASSESSMENT

Please rank.	disagree			agree
16)	1	2	3	4
I can identify drugs that require pharmacogenomics testing.	0	О	0	0
Please rank.	disagree			agree
17)	1	2	3	4
I am confident that I can use the results of pharmacogenomics tests to make an appropriate adjustment to a patient's drug therapy.	0	0	0	0

18)

To adjust therapy based on pharmacogenomics tests (more often) I would need...

(please select all that apply) o better knowledge on genetics

o better knowledge on pharmacology

o better knowledge on drug metabolism

o better knowledge on the basic concepts of

pharmacogenomics

o a better evidence base that pharmacogenomics improves

clinical outcomes

o better ability to apply my knowledge

o better knowledge of legal regulations o support of my working institution

o insurance coverage

o expert counsel

(if other, please specify) o other:

_		
	u	

What would be your preferred format for learning more about pharmacogenomics in the future?

(please select all that apply) o scienti

o scientific article o conference talk

o accredited learning course

o continuing medical education-accredited workshop

o patient cases o medical app

o medical app

o e-learning course

(if other, please specify) o other: _____

20)

How much time would you spend on an e-learning program on pharmacogenomics?

o < 30 minutes

o 30 minutes

o 60 minutes

o 90 minutes

SECTION 5: DEMOGRAPHICS Please tell us: 21) Your year of birth? 22) Your gender? o male o female 23) Your profession? o pharmacist (please select what applies best) o physician (if other, please specify) o other: _ 24) In which country do you work? o Austria o Great Britain o Greece o Italy o Netherlands o Slovenia o Spain 25) Number of years working within your profession since graduating from university? o 1 o 2-5 o 6-10 o 11-20 o >20 26) What is your primary practice setting? o hospital outpatients or ambulatory care (please select what applies best) o hospital inpatients o community-based nursing home o academia o research

(if other, please specify) o other: _____

27)	
What is your speciality? (one)	o anaesthetics
	o biochemistry
	o cardiology
	o clinical pharmacology
	o emergency or acute medicine
	o endocrinology and diabetes
	o gastroenterology
	o general pharmacy
	o genetics
	o infectious diseases and microbiology
	o haematology
	o hospital pharmacy
	o nephrology
	o neurology
	o obstetrics/gynaecology
	o oncology
	o pathology
	o paediatrics
	o primary care/ family medicine
	o psychiatry
	o radiology
	o respiratory
	o rheumatology
	o surgery
(if other	r, please specify) o other:

	n۱	
,	ХI	
	Οı	

How would you describe your practice setting? (one)

o university/academic
o urban
o suburban
o rural
(if other, please specify)

o other:

29)

Please list any additional comments or feedback here: (max. 250 words)